Obesity is associated with increased asthma morbidity. Observational reports have suggested that therapies targeting the glucagon-like peptide-1 (GLP-1) pathway may influence respiratory outcomes, but treatment selection and confounding can bias such associations. The investigators examined real-world electronic health record data to compare asthma-related outcomes among adults with obesity who initiated GLP-1-based therapy versus those who initiated other active pharmacologic weight-management treatments.
This was an active-comparator retrospective cohort study performed using the TriNetX US Collaborative Network, which aggregates data from 72 healthcare organizations. The analysis aimed to reduce confounding through an active comparator and propensity-score matching, then to evaluate recorded respiratory and utilization outcomes over a one-year period after treatment initiation.
Included patients were adults with body mass index (BMI) ≥30 kg/m2 and repeated documentation of asthma, who subsequently received either GLP-1-based therapy or an active non-GLP pharmacologic weight-management therapy. After 1:1 propensity-score matching, the analytic sample comprised 2,423 patients in the GLP-1 cohort and 2,423 matched patients in the comparator cohort. The study assessed outcomes from day 1 through day 365 following the treatment-aligned index event.
Outcomes were captured in electronic health records and included recorded asthma exacerbations, systemic glucocorticoid exposure, emergency department (ED) or critical-care utilization, and acute respiratory failure. Outcomes were ascertained over a fixed one-year follow-up window (day 1 to day 365 after index).
Recorded asthma exacerbation within one year occurred in 1.7% of patients in the GLP-1 cohort versus 4.0% in the active non-GLP comparator cohort. The absolute risk difference was −2.2% (95% confidence interval [CI], −3.2% to −1.3%). The risk ratio (RR) for exacerbation with GLP-1-based therapy was 0.438 (95% CI, 0.306–0.626), indicating a lower recorded rate of exacerbation in the GLP-1 group compared with the matched comparator.
GLP-1-based therapy was associated with lower systemic glucocorticoid exposure over one year: 16.4% of the GLP-1 cohort versus 23.1% in the comparator cohort (RR 0.712). Emergency department or critical-care utilization was also reduced (7.1% vs 13.0%; RR 0.541). Incidence of acute respiratory failure was lower in the GLP-1 group (0.7% vs 1.8%; RR 0.364). These outcomes suggest reduced acute care needs and systemic steroid exposure among patients receiving GLP-1-based therapy in this matched observational sample.
The authors report that sensitivity analyses restricted by BMI and glycated hemoglobin (HbA1c) were generally directionally concordant with the primary findings. Specific numerical results of the sensitivity analyses were not provided in the abstract.
The dataset and analysis did not systematically assess GLP-1-specific adverse events. The investigators note that GLP-1-specific safety signals were not evaluated comprehensively in this study based on the information provided in the abstract.
The authors highlight several limitations that preclude causal inference from these observational data. Residual confounding remains possible despite propensity-score matching and the use of an active comparator. Treatment persistence and actual medication exposure over the follow-up period are uncertain in the electronic health record data. In addition, exposure and outcome misclassification could affect results because ascertainment relied on recorded codes and documentation. The abstract does not provide granular details about matching covariates, adherence, or exact variable definitions.
In this large, propensity-matched retrospective cohort of adults with obesity and asthma, initiation of GLP-1-based therapy was associated with fewer recorded one-year respiratory events, lower systemic glucocorticoid exposure, and reduced ED/critical-care utilization compared with active non-GLP pharmacologic weight-management therapy. However, because of residual confounding, uncertain treatment persistence, and potential misclassification of exposures and outcomes, the study does not establish causality. The results support further prospective and mechanistic research to evaluate whether GLP-1 pathway therapies directly improve asthma outcomes in patients with obesity and to characterize safety in this population.
Keywords: Asthma; GLP-1 receptor agonists; obesity; propensity-score matching; tirzepatide.